Voyager Therapeutics (NASDAQ:VYGR) Shares Break Below Fifty Day Moving Average - Here's What Happened

Key Points

• Voyager Therapeutics shares fell 4.3%, trading as low as $2.64 and closing at $2.68, below the 50-day moving average of $3.21 and the 200-day average of $3.60.
• Analyst sentiment remains mixed but leans positive, with one Strong Buy, two Buy, and one Sell rating; the consensus rating is Moderate Buy with a $16.50 target price.
• The company reported a quarterly loss of $0.40 per share, better than the expected $0.48 loss, but revenue of $3.17 million missed estimates and profitability metrics remained sharply negative.

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) shares passed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $3.21 and traded as low as $2.64. Voyager Therapeutics shares last traded at $2.68, with a volume of 719,918 shares.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on VYGR. Weiss Ratings reiterated a "sell (d-)" rating on shares of Voyager Therapeutics in a report on Monday, July 13th. HC Wainwright restated a "buy" rating on shares of Voyager Therapeutics in a research note on Thursday, August 27th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.50.

Voyager Therapeutics Trading Down 4.3%

The company's 50 day moving average is $3.21 and its 200-day moving average is $3.60. The stock has a market cap of $165.14 million, a PE ratio of -1.49 and a beta of 1.32.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.08. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%.The firm had revenue of $3.17 million during the quarter, compared to the consensus estimate of $4.52 million. As a group, analysts forecast that Voyager Therapeutics, Inc. will post -1.63 EPS for the current year.

Institutional Trading of Voyager Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Voyager Therapeutics during the 2nd quarter valued at about $18,102,000. EcoR1 Capital LLC lifted its position in Voyager Therapeutics by 497.2% in the fourth quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company's stock worth $15,731,000 after purchasing an additional 3,332,544 shares during the period. Erste Asset Management GmbH lifted its holdings in shares of Voyager Therapeutics by 7.0% in the fourth quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company's stock valued at $4,718,000 after buying an additional 78,348 shares during the period. Opaleye Management Inc. boosted its position in shares of Voyager Therapeutics by 3.0% during the 2nd quarter. Opaleye Management Inc. now owns 1,185,000 shares of the company's stock valued at $4,148,000 after purchasing an additional 35,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Voyager Therapeutics by 95.0% in the 1st quarter. Renaissance Technologies LLC now owns 578,024 shares of the company's stock worth $2,231,000 after purchasing an additional 281,574 shares during the last quarter. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc NASDAQ: VYGR is a clinical-stage biotechnology company focused on developing gene therapies and other medicines for diseases of the central nervous system. The company seeks to address neurological conditions by delivering therapeutic genetic material to specific cells in the brain and spinal cord.

Voyager's technology platform includes its TRACER AAV capsid discovery platform, which is designed to identify adeno-associated virus capsids that can cross the blood-brain barrier and enable broader distribution of gene therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.